Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE).
paper
Cited
Public
Unavailable
- Authors
- Vestbo, J; Anderson, W; Coxson, H O; Crim, C; Dawber, F; Edwards, L; Hagan, G; Knobil, K; Lomas, D A; MacNee, W; Silverman, E K; Tal-Singer, R; ECLIPSE investigators
- Year
- 2008
- Journal
- The European respiratory journal
- PMID
- 18216052
- DOI
- 10.1183/09031936.00111707
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease and not well understood. The forced expiratory volume in one second is used for the diagnosis and staging of COPD, but there is wide acceptance that it is a crude measure and insensitive to change over shorter periods of time. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) is a 3-yr longitudinal study with four specific aims: 1) definition of clinically relevant COPD subtypes; 2) identification of parameters that predict disease progression in these subtypes; 3) examination of biomarkers that correlate with COPD subtypes and may predict disease progression; and 4) identification of novel genetic factors and/or biomarkers that both correlate with clinically relevant COPD subtypes and predict disease progression. ECLIPSE plans to recruit 2,180 COPD subjects in Global Initiative for Chronic Obstructive Lung Disease categories II-IV and 343 smoking and 223 nonsmoking control subjects. Study procedures are to be performed at baseline, 3 months, 6 months and every 6 months thereafter. Assessments include pulmonary function measurements (spirometry, impulse oscillometry and plethysmography), chest computed tomography, biomarker measurement (in blood, sputum, urine and exhaled breath condensate), health outcomes, body impedance, resting oxygen saturation and 6-min walking distance. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points is the largest study attempting to better describe the subtypes of chronic obstructive pulmonary disease, as well as defining predictive markers of its progression.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A simple index for predicting mucus plugs in patients with chronic obstructive pulmonary disease. | Wang W et al. | — | 2026 | → |
| Maternal smoking and CC-16: implications for lung development and COPD across the lifespan. | Rojas-Quintero J et al. | — | 2026 | → |
| Multi-ancestry genome-wide association study and meta-analysis of lung function decline. | Patchen BK et al. | — | 2026 | → |
| Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) model. | Aung HWW et al. | — | 2026 | → |
| Prognostic score for predicting respiratory admissions among patients with chronic obstructive pulmonary disease in primary care: development and validation in population cohorts (Birmingham Lung Improvement Studies (BLISS)). | Jordan RE et al. | — | 2026 | → |
| Understanding exacerbation risk in BLVR: A logistic regression approach to complication prediction. | Wienker J et al. | — | 2026 | → |
| Whole genome sequence analysis of pulmonary function and COPD in 44,287 multi-ancestry participants. | Kim W et al. | — | 2026 | → |
| Airway Mucus Plugs on Chest Computed Tomography Are Associated with Exacerbations in Chronic Obstructive Pulmonary Disease. | Wan E et al. | — | 2025 | → |
| Analysis of research trends and hot spots on COPD biomarkers from the perspective of bibliometrics. | Liu Y et al. | — | 2025 | → |
| Automated CT-based measurements of radial and longitudinal expansion of airways due to breathing-related lung volume change. | Nadeem SA et al. | — | 2025 | → |
| Bronchodilator reversibility and eosinophilic biomarkers in chronic obstructive pulmonary disease patients. | Ameet H et al. | — | 2025 | → |
| Characteristics and actions in high-risk COPD in unstable patients: The EPOCONSUL audit. | Calle Rubio M et al. | — | 2025 | → |
| Chronic Obstructive Pulmonary Disease and Metabolic Syndrome: A Maltese Study on Biomarkers and Clinical Implications. | Gauci J et al. | — | 2025 | → |
| Comorbidity profiles in chronic obstructive pulmonary disease: a multicohort study. | Egerod L et al. | — | 2025 | → |
| Contrasting the clinical and biological characteristics of young and old COPD patients. | Vila M et al. | — | 2025 | → |
| COPD-associated proteins as biomarkers and drug targets: Insights from genetic and proteomic analyses. | Lin X et al. | — | 2025 | → |
| Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK. | Cai R et al. | — | 2025 | → |
| Emphysema progression risk in COPD using a localized foundational model of density evolution. | Curiale AH et al. | — | 2025 | → |
| GOLD grade-specific characterization of COPD in the COSYCONET multi-center trial: comparison of semiquantitative MRI and quantitative CT. | Konietzke P et al. | — | 2025 | → |
| Harmonized low-dose computed tomographic protocols for quantitative lung imaging using dose modulation and advanced reconstructions. | Atha J et al. | — | 2025 | → |
| Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal? | Singh D et al. | — | 2025 | → |
| LaGrACE: estimating gene program dysregulation with latent regulatory network. | Jia M et al. | — | 2025 | → |
| Molecular determinants of lung function decline: a multi-level analysis of gene expression. | Elhusseini ZW et al. | — | 2025 | → |
| Moving Beyond Air Trapping with Expiratory CT Radiomics: A Timely Reminder. | Chaudhary MFA | — | 2025 | → |
| Navigating the Progression of Chronic Obstructive Pulmonary Disease. | Pistenmaa C et al. | — | 2025 | → |
| Novel Lobe-based Transformer model (LobTe) to predict emphysema progression in Alpha-1 Antitrypsin Deficiency. | Curiale AH et al. | — | 2025 | → |
| Novel risk loci encompassing genes influencing STAT3, GPCR, and oxidative stress signaling are associated with co-morbid GERD and COPD. | Wilson AC et al. | — | 2025 | → |
| NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome. | Gopalakrishnan V et al. | — | 2025 | → |
| Optimizing convolutional neural networks for Chronic Obstructive Pulmonary Disease detection in clinical computed tomography imaging. | Dorosti T et al. | — | 2025 | → |
| Oxidative Stress and Inflammation in Hypoxemic Respiratory Diseases and Their Comorbidities: Molecular Insights and Diagnostic Advances in Chronic Obstructive Pulmonary Disease and Sleep Apnea. | Rodríguez-Pérez J et al. | — | 2025 | → |
| Phenotyping Chronic Obstructive Pulmonary Disease Through Principal Component Analysis: Identification of Clinical Clusters. | Mekov EV et al. | — | 2025 | → |
| Plasma IgG Glycosylation Profiling Reveals the Biological Features of Early Chronic Obstructive Pulmonary Disease. | Zhou J et al. | — | 2025 | → |
| Potential Causal Relationship Between Chronic Obstructive Pulmonary Disease and Diabetes: A Bidirectional Two-Sample Mendelian Randomization Study. | Wang X et al. | — | 2025 | → |
| Protective factors against oxidative stress in COPD: focus on Nrf2-dependent antioxidant gene expression. | Kominkova E et al. | — | 2025 | → |
| Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy. | See XY et al. | — | 2025 | → |
| Rationale and Design of the Alpha-1 Biomarkers Consortium Study. | Goldklang MP et al. | — | 2025 | → |
| Seeing is Believing-On the Utility of CT in Phenotyping COPD. | Awan HA et al. | — | 2025 | → |
| The use of the Prospector calculator reduces antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. | Paprocki M et al. | — | 2025 | → |
| Accelerated elastin degradation by age-disease interaction: a common feature in age-related diseases. | Shek N et al. | — | 2024 | → |
| A fully automated pipeline for the extraction of pectoralis muscle area from chest computed tomography scans. | Genkin D et al. | — | 2024 | → |
| An integrative network-based approach to identify driving gene communities in chronic obstructive pulmonary disease. | Marino R et al. | — | 2024 | → |
| Blood-based Transcriptomic and Proteomic Biomarkers of Emphysema. | Suryadevara R et al. | — | 2024 | → |
| Blood eosinophils levels in a Colombian cohort of biomass-and tobacco-related COPD patients. | García Morales OM et al. | — | 2024 | → |
| Cell-free DNA levels associate with COPD exacerbations and mortality. | Ware SA et al. | — | 2024 | → |
| Chest CT-based automated vertebral fracture assessment using artificial intelligence and morphologic features. | Nadeem SA et al. | — | 2024 | → |
| Delphi Consensus on Clinical Applications of GOLD 2023 Recommendations in COPD Management: How Aligned are Recommendations with Clinical Practice? | Anzueto A et al. | — | 2024 | → |
| Development and validation of a mortality risk prediction model for chronic obstructive pulmonary disease: a cross-sectional study using probabilistic graphical modelling. | Lovelace TC et al. | — | 2024 | → |
| Development and validation of a prediction score to assess the risk of incurring in COPD-related exacerbations: a population-based study in primary care. | Lapi F et al. | — | 2024 | → |
| Endotypes of Paediatric Cough-Do They Exist and Finding New Techniques to Improve Clinical Outcomes. | O'Farrell HE et al. | — | 2024 | → |
| Factors Affecting Survival in Severe and Very Severe COPD after Admission in ICUs of Tertiary Care Centers of India (FAST COPD): Study Protocol for a Multicentric Cohort Study. | Arunachala S et al. | — | 2024 | → |
| Factors Associated with the Discrepancy between Exercise Capacity and Airflow Limitation in Patients with Chronic Obstructive Pulmonary Disease. | Kim TH et al. | — | 2024 | → |
| Genetically Predicted Body Mass Index and Mortality in Chronic Obstructive Pulmonary Disease. | Zhang J et al. | — | 2024 | → |
| Genome-wide association study identifies novel susceptible loci and evaluation of polygenic risk score for chronic obstructive pulmonary disease in a Taiwanese population. | Lin WD et al. | — | 2024 | → |
| Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience. | de-Torres JP et al. | — | 2024 | → |
| Impact of Smoking and Chronic Obstructive Pulmonary Disease on All-Cause, Respiratory, and Cardio-Cerebrovascular Mortality. | Kang HR et al. | — | 2024 | → |
| Multi-center Korean cohort study based on RNA-sequencing data targeting COPD patients. | Seo M et al. | — | 2024 | → |
| Phenotyping of COPD with MRI in comparison to same-day CT in a multi-centre trial. | Nauck S et al. | — | 2024 | → |
| Polygenic and transcriptional risk scores identify chronic obstructive pulmonary disease subtypes in the COPDGene and ECLIPSE cohort studies. | Moll M et al. | — | 2024 | → |
| Stakeholder-informed positivity thresholds for disease markers and risk scores: a methodological framework and an application in obstructive lung disease. | Sadatsafavi M et al. | — | 2024 | → |
| The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada - The IMPACT trial. | Risebrough NA et al. | — | 2024 | → |
| The Natural History of Severe Chronic Obstructive Pulmonary Disease: The SPOCCAT Study Protocol. | González J et al. | — | 2024 | → |
| A Survey on Artificial Intelligence in Pulmonary Imaging. | Saha PK et al. | — | 2023 | → |
| Baseline characteristics from a 3-year longitudinal study to phenotype subjects with COPD: the FOOTPRINTS study. | Crapo JD et al. | — | 2023 | → |
| Blood Gene Expression and Immune Cell Subtypes Associated with Chronic Obstructive Pulmonary Disease Exacerbations. | Ryu MH et al. | — | 2023 | → |
| Chest MRI and CT Predictors of 10-Year All-Cause Mortality in COPD. | Sharma M et al. | — | 2023 | → |
| Chronic Obstructive Pulmonary Disease: Novel Genes Detection with Penalized Logistic Regression. | Gohari K et al. | — | 2023 | → |
| Circulating testosterone levels and health outcomes in chronic obstructive pulmonary disease: results from ECLIPSE and ERICA. | Pavey H et al. | — | 2023 | → |
| Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK. | Kendall R et al. | — | 2023 | → |
| Impact of Interstitial Lung Abnormalities on Disease Expression and Outcomes in COPD or Emphysema: A Systematic Review. | Liu Y et al. | — | 2023 | → |
| Machine learning and deep learning predictive models for long-term prognosis in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. | Smith LA et al. | — | 2023 | → |
| Metabolomics in COPD. | Gea J et al. | — | 2023 | → |
| Phenotyping asthma with airflow obstruction in middle-aged and older adults: a CADSET clinical research collaboration. | Bertels X et al. | — | 2023 | → |
| Radiomics for Improved Detection of Chronic Obstructive Pulmonary Disease in Low-Dose and Standard-Dose Chest CT Scans. | Amudala Puchakayala PR et al. | — | 2023 | → |
| Research on the effectiveness and safety of bronchial thermoplasty in patients with chronic obstructive pulmonary disease. | Wang T et al. | — | 2023 | → |
| Sample size estimation for comparing dynamic treatment regimens in a SMART: A Monte Carlo-based approach and case study with longitudinal overdispersed count outcomes. | Yap J et al. | — | 2023 | → |
| The utility of quantitative computed tomography in cohort studies of chronic obstructive pulmonary disease: a narrative review. | Dai Q et al. | — | 2023 | → |
| Update on metabolomic findings in COPD patients. | Gea J et al. | — | 2023 | → |
| X chromosome associations with chronic obstructive pulmonary disease and related phenotypes: an X chromosome-wide association study. | Hayden LP et al. | — | 2023 | → |
| ACCEPT 2·0: Recalibrating and externally validating the Acute COPD exacerbation prediction tool (ACCEPT). | Safari A et al. | — | 2022 | → |
| A genome-wide association study of bronchodilator response in participants of European and African ancestry from six independent cohorts. | Gereige JD et al. | — | 2022 | → |
| Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. | Ghosh AJ et al. | — | 2022 | → |
| Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities. | Kim JS et al. | — | 2022 | → |
| Blood gene expression risk profiles and interstitial lung abnormalities: COPDGene and ECLIPSE cohort studies. | Moll M et al. | — | 2022 | → |
| Circulating eosinophil levels and lung function decline in stable chronic obstructive pulmonary disease: a retrospective longitudinal study. | Ferrari M et al. | — | 2022 | → |
| Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system. | Balmaceda C et al. | — | 2022 | → |
| Development of a Blood-based Transcriptional Risk Score for Chronic Obstructive Pulmonary Disease. | Moll M et al. | — | 2022 | → |
| Factors affecting length of hospital stay in chronic obstructive pulmonary disease patients in a tertiary hospital of Nepal: A retrospective cross-sectional study. | Pokharel P et al. | — | 2022 | → |
| GAWMerge expands GWAS sample size and diversity by combining array-based genotyping and whole-genome sequencing. | Mathur R et al. | — | 2022 | → |
| Increased monocyte level is a risk factor for radiological progression in patients with early fibrotic interstitial lung abnormality. | Achaiah A et al. | — | 2022 | → |
| Longitudinal Association Between Muscle Loss and Mortality in Ever Smokers. | Mason SE et al. | — | 2022 | → |
| <i>C</i> <i>FTR</i> variants are associated with chronic bronchitis in smokers. | Saferali A et al. | — | 2022 | → |
| Lung volumes measurement using novel pressure derived method in participants with obstructive, restrictive and healthy lungs. | Zac J et al. | — | 2022 | → |
| Metabolome Features of COPD: A Scoping Review. | Godbole S et al. | — | 2022 | → |
| Study on factors associated with post bronchodilator reversibility among patients presenting with dyspnea: An experience at a tertiary care academic hospital in Kerala. | Mehta AA et al. | — | 2022 | → |
| Abnormal pulmonary flow is associated with impaired right ventricular coupling in patients with COPD. | Oganesyan A et al. | — | 2021 | → |
| A Prospective Cohort Study to Assess Obstructive Respiratory Disease Phenotypes and Endotypes in Japan: The TRAIT Study Design. | Hizawa N et al. | — | 2021 | → |
| Associations between bone attenuation and prevalent vertebral fractures on chest CT scans differ with vertebral fracture locations. | Driessen JHM et al. | — | 2021 | → |
| Catching "Early" COPD - The Diagnostic Conundrum. | Yip KP et al. | — | 2021 | → |
| Circulating Secretoglobin Family 1A Member 1 (SCGB1A1) Levels as a Marker of Biomass Smoke Induced Chronic Obstructive Pulmonary Disease. | Veerapaneni VV et al. | — | 2021 | → |
| Correlation between Telomere Length and Chronic Obstructive Pulmonary Disease-Related Phenotypes: Results from the Chronic Obstructive Pulmonary Disease in Dusty Areas (CODA) Cohort. | Moon DH et al. | — | 2021 | → |
| CT Imaging and Comorbidities in COPD: Beyond Lung Cancer Screening. | Singhvi D et al. | — | 2021 | → |
| CT Pulmonary Vessels and MRI Ventilation in Chronic Obstructive Pulmonary Disease: Relationship with worsening FEV<sub>1</sub> in the TINCan cohort study. | Barker AL et al. | — | 2021 | → |
| Dyspnoea and symptom burden in mild-moderate COPD: the Canadian Cohort Obstructive Lung Disease Study. | Cherian M et al. | — | 2021 | → |
| Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. | Shukla S et al. | — | 2021 | → |
| Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials. | Begg M et al. | — | 2021 | → |
| Factors Influencing the Length of Hospital Stay Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in Macao Population: A Retrospective Study of Inpatient Health Record. | Li M et al. | — | 2021 | → |
| FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD. | Crapo J et al. | — | 2021 | → |
| Gender modifies the effect of body mass index on lung function decline in mild-to-moderate COPD patients: a pooled analysis. | Chen W et al. | — | 2021 | → |
| Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation. | Hosking L et al. | — | 2021 | → |
| Genetic variation in genes regulating skeletal muscle regeneration and tissue remodelling associated with weight loss in chronic obstructive pulmonary disease. | Lakshman Kumar P et al. | — | 2021 | → |
| Genome-Wide Gene-by-Smoking Interaction Study of Chronic Obstructive Pulmonary Disease. | Kim W et al. | — | 2021 | → |
| Identification of Metabolism-Associated Molecular Subtypes of Chronic Obstructive Pulmonary Disease. | Hu Y et al. | — | 2021 | → |
| Implication of RAGE Polymorphic Variants in COPD Complication and Anti-COPD Therapeutic Potential of sRAGE. | Malik P et al. | — | 2021 | → |
| Influenza Vaccination and the Risk of Ventricular Arrhythmias in Patients With Chronic Obstructive Pulmonary Disease: A Population-Based Longitudinal Study. | Chen CC et al. | — | 2021 | → |
| Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale. | Liang Z et al. | — | 2021 | → |
| Lung function trajectory and biomarkers in the Tasmanian Longitudinal Health Study. | Bui DS et al. | — | 2021 | → |
| Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. | Celli B et al. | — | 2021 | → |
| Moving beyond AUC: decision curve analysis for quantifying net benefit of risk prediction models. | Sadatsafavi M et al. | — | 2021 | → |
| PARC/CCL18 is Associated with Inflammation, Emphysema Severity and Application of Inhaled Corticosteroids in Hospitalized COPD Patients. | Duan H et al. | — | 2021 | → |
| Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort. | Meeraus WH et al. | — | 2021 | → |
| Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. | Han MK et al. | — | 2021 | → |
| Protein Biomarkers for COPD Outcomes. | Serban KA et al. | — | 2021 | → |
| Relationship between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDGene and ECLIPSE Cohorts. | Ash SY et al. | — | 2021 | → |
| Respiratory exacerbations are associated with muscle loss in current and former smokers. | Mason SE et al. | — | 2021 | → |
| Should the number of acute exacerbations in the previous year be used to guide treatments in COPD? | Sadatsafavi M et al. | — | 2021 | → |
| Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD. | Pratte KA et al. | — | 2021 | → |
| The association of silicosis severity with pectoralis major muscle and subcutaneous fat volumes and the pulmonary artery/aorta ratio evaluated by CT. | Yılmaz Çankaya B et al. | — | 2021 | → |
| The different phenotypes of COPD. | Yousuf A et al. | — | 2021 | → |
| The lower the eosinophils, the stronger the inflammatory response? The relationship of different levels of eosinophils with the degree of inflammation in acute exacerbation chronic obstructive pulmonary disease (AECOPD). | Lv MY et al. | — | 2021 | → |
| Update on guidelines for the treatment of COPD in Taiwan using evidence and GRADE system-based recommendations. | Cheng SL et al. | — | 2021 | → |
| Using Blood Eosinophil Count as a Biomarker to Guide Corticosteroid Treatment for Chronic Obstructive Pulmonary Disease. | Sivapalan P et al. | — | 2021 | → |
| A cross-omics integrative study of metabolic signatures of chronic obstructive pulmonary disease. | Prokić I et al. | — | 2020 | → |
| Adult Life-Course Trajectories of Lung Function and the Development of Emphysema: The CARDIA Lung Study. | Washko GR et al. | — | 2020 | → |
| Advances in Chronic Obstructive Pulmonary Disease Imaging. | Dolliver WR et al. | — | 2020 | → |
| Artificial Intelligence in COPD: New Venues to Study a Complex Disease. | Estépar RSJ | — | 2020 | → |
| Association between vertebral fractures and coronary artery calcification in current and former smokers in the ECLIPSE cohort. | van Dort MJ et al. | — | 2020 | → |
| Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape. | Gromova M et al. | — | 2020 | → |
| Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. | Lonergan M et al. | — | 2020 | → |
| Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. | Moll M et al. | — | 2020 | → |
| Combining biomarkers of clot resolution and alveolar basement membrane destruction predicts mortality in the ECLIPSE COPD cohort. | Sand JMB et al. | — | 2020 | → |
| Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective. | Schroeder M et al. | — | 2020 | → |
| Deep Learning Enables Automatic Classification of Emphysema Pattern at CT. | Humphries SM et al. | — | 2020 | → |
| Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. | Young AL et al. | — | 2020 | → |
| Endotrophin, an extracellular hormone, in combination with neoepitope markers of von Willebrand factor improves prediction of mortality in the ECLIPSE COPD cohort. | Rønnow SR et al. | — | 2020 | → |
| Extracellular matrix remodelling in COPD. | Karakioulaki M et al. | — | 2020 | → |
| Fractional Exhaled Nitric Oxide as an Inflammatory Biomarker in Chronic Obstructive Pulmonary Disease (COPD) with or without Concurrent Diagnosis of Asthma: The Canadian Cohort Obstructive Lung Disease (CanCOLD). | Mostafavi-Pour-Manshadi SM et al. | — | 2020 | → |
| Genetic variants in IL17A and serum levels of IL-17A are associated with COPD related to tobacco smoking and biomass burning. | Ponce-Gallegos MA et al. | — | 2020 | → |
| Heart Failure is Highly Prevalent and Difficult to Diagnose in Severe Exacerbations of COPD Presenting to the Emergency Department. | Tinè M et al. | — | 2020 | → |
| Heme metabolism genes Downregulated in COPD Cachexia. | Wilson AC et al. | — | 2020 | → |
| Increased von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, Is Associated with Emphysema, Exacerbations and Elevated Mortality Risk. | Langholm LL et al. | — | 2020 | → |
| Inter- and intra-software reproducibility of computed tomography lung density measurements. | Kirby M et al. | — | 2020 | → |
| KMBARC registry: protocol for a multicentre observational cohort study on non-cystic fibrosis bronchiectasis in Korea. | Lee H et al. | — | 2020 | → |
| Measuring disease activity in COPD: is clinically important deterioration the answer? | Singh D et al. | — | 2020 | → |
| Moderate and severe exacerbations have a significant impact on health-related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: A meta-analysis. | Guo J et al. | — | 2020 | → |
| Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design. | Vestbo J et al. | — | 2020 | → |
| Phenotypic characterisation of early COPD: a prospective case-control study. | Cosío BG et al. | — | 2020 | → |
| Protective effect of club cell secretory protein (CC-16) on COPD risk and progression: a Mendelian randomisation study. | Milne S et al. | — | 2020 | → |
| Pulmonary Imaging Phenotypes of Chronic Obstructive Pulmonary Disease Using Multiparametric Response Maps. | MacNeil JL et al. | — | 2020 | → |
| Relative contributions of family history and a polygenic risk score on COPD and related outcomes: COPDGene and ECLIPSE studies. | Moll M et al. | — | 2020 | → |
| Relative Contributions of Family History and a Polygenic Risk Score on COPD and Related Outcomes: COPDGene and ECLIPSE studies | Moll M et al. | — | 2020 | — |
| Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study. | Fermont JM et al. | — | 2020 | → |
| Role of the Bronchodilator Test Defined by the Forced Vital Capacity in Chronic Obstructive Pulmonary Disease Phenotyping. | Zhang X et al. | — | 2020 | → |
| The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. | Zhou A et al. | — | 2020 | → |
| Towards large-scale case-finding: training and validation of residual networks for detection of chronic obstructive pulmonary disease using low-dose CT. | Tang LYW et al. | — | 2020 | → |
| Treatable traits qualifying for nonpharmacological interventions in COPD patients upon first referral to a pulmonologist: the COPD sTRAITosphere. | van 't Hul AJ et al. | — | 2020 | → |
| Using Quantitative Computed Tomographic Imaging to Understand Chronic Obstructive Pulmonary Disease and Fibrotic Interstitial Lung Disease: State of the Art and Future Directions. | Castillo-Saldana D et al. | — | 2020 | → |
| Validation of a method to assess emphysema severity by spirometry in the COPDGene study. | Occhipinti M et al. | — | 2020 | → |
| Vitamin D Metabolism Is Dysregulated in Asthma and Chronic Obstructive Pulmonary Disease. | Jolliffe DA et al. | — | 2020 | → |
| A Cross-Sectional Study in Patients with Severe COPD to Assess the Perception of Symptom Variability (COPVAR) in the Middle East and Africa. | Kokturk N et al. | — | 2019 | → |
| A pilot study to test the feasibility of histological characterisation of asthma-COPD overlap. | Papakonstantinou E et al. | — | 2019 | → |
| BMI is associated with FEV<sub>1</sub> decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials. | Sun Y et al. | — | 2019 | → |
| Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study. | Maselli DJ et al. | — | 2019 | → |
| Common and Rare Variants Genetic Association Analysis of Cigarettes per Day Among Ever-Smokers in Chronic Obstructive Pulmonary Disease Cases and Controls. | Lutz SM et al. | — | 2019 | → |
| Computational modeling of lung deposition of inhaled particles in chronic obstructive pulmonary disease (COPD) patients: identification of gaps in knowledge and data. | Ganguly K et al. | — | 2019 | → |
| Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial. | Ismaila AS et al. | — | 2019 | → |
| Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. | Criner GJ et al. | — | 2019 | → |
| Defining severe obstructive lung disease in the biologic era: an endotype-based approach. | Martin RJ et al. | — | 2019 | → |
| Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada. | Sadatsafavi M et al. | — | 2019 | → |
| Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion. | Lan G et al. | — | 2019 | → |
| Disruption of histidine and energy homeostasis in chronic obstructive pulmonary disease. | Diao W et al. | — | 2019 | → |
| DSP variants may be associated with longitudinal change in quantitative emphysema. | Kim W et al. | — | 2019 | → |
| Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD. | Kurian N et al. | — | 2019 | → |
| Effects of Acute and Chronic Exposure to Residual Level Erythromycin on Human Intestinal Epithelium Cell Permeability and Cytotoxicity. | Hao H et al. | — | 2019 | → |
| Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. | Vogelmeier CF et al. | — | 2019 | → |
| Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. | Cazzola M et al. | — | 2019 | → |
| How different are COPD-specific patient reported outcomes, health status, dyspnoea and respiratory symptoms? An observational study in a working population. | Nishimura K et al. | — | 2019 | → |
| Identification of an emphysema-associated genetic variant near <i>TGFB2</i> with regulatory effects in lung fibroblasts. | Parker MM et al. | — | 2019 | → |
| Increased Airway Wall Thickness in Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. | Miller ER et al. | — | 2019 | → |
| It's more than low BMI: prevalence of cachexia and associated mortality in COPD. | McDonald MN et al. | — | 2019 | → |
| Joint Indian Chest Society-National College of Chest Physicians (India) guidelines for spirometry. | Aggarwal AN et al. | — | 2019 | → |
| Longitudinal airway remodeling in active and past smokers in a lung cancer screening population. | Jobst BJ et al. | — | 2019 | → |
| Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. | Paly VF et al. | — | 2019 | → |
| Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis. | Viglino D et al. | — | 2019 | → |
| Machine Learning Algorithms Utilizing Functional Respiratory Imaging May Predict COPD Exacerbations. | Lanclus M et al. | — | 2019 | → |
| Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. | Chan SMH et al. | — | 2019 | → |
| Peripheral Blood Eosinophil as a Biomarker in Outcomes of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. | Wu HX et al. | — | 2019 | → |
| Prediction of Treatment Response in Patients with Chronic Obstructive Pulmonary Disease by Determination of Airway Dimensions with Baseline Computed Tomography. | Park HJ et al. | — | 2019 | → |
| Prevalence and features of asthma-chronic obstructive pulmonary disease overlap in Northern Italy general population. | Guerriero M et al. | — | 2019 | → |
| Research highlights from the 2018 European Respiratory Society International Congress: airway disease. | Schleich F et al. | — | 2019 | → |
| Revealing Methodological Challenges in Chronic Obstructive Pulmonary Disease Studies Assessing Comorbidities: A Narrative Review. | Houben-Wilke S et al. | — | 2019 | → |
| Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort. | Rønnow SR et al. | — | 2019 | → |
| Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV<sub>1</sub>/FVC. | Hoesterey D et al. | — | 2019 | → |
| The present and future of deep learning in radiology. | Saba L et al. | — | 2019 | → |
| Thoracic Kyphosis on Chest CT Scans Is Associated With Incident Vertebral Fractures in Smokers. | van Dort MJ et al. | — | 2019 | → |
| Traditional Chinese exercise (TCE) on pulmonary rehabilitation in patients with stable chronic obstructive pulmonary disease: Protocol for a systematic review and network meta-analysis. | Zheng W et al. | — | 2019 | → |
| Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort. | Rønnow SR et al. | — | 2019 | → |
| Vertebral bone attenuation in Hounsfield Units and prevalent vertebral fractures are associated with the short-term risk of vertebral fractures in current and ex-smokers with and without COPD: a 3-year chest CT follow-up study. | van Dort MJ et al. | — | 2019 | → |
| Artificial Intelligence and Chest Imaging. Will Deep Learning Make Us Smarter? | Labaki WW et al. | — | 2018 | → |
| Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. | Yun JH et al. | — | 2018 | → |
| Current Approaches for Phenotyping as a Target for Precision Medicine in COPD Management. | Lopez-Campos JL et al. | — | 2018 | → |
| Defining Impaired Respiratory Health. A Paradigm Shift for Pulmonary Medicine. | Reyfman PA et al. | — | 2018 | → |
| Development of a pulmonary imaging biomarker pipeline for phenotyping of chronic lung disease. | Guo F et al. | — | 2018 | → |
| Disease Staging and Prognosis in Smokers Using Deep Learning in Chest Computed Tomography. | González G et al. | — | 2018 | → |
| Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort. | Faner R et al. | — | 2018 | → |
| Effects of Roflumilast on Rehospitalization and Mortality in Patients. | Criner GJ et al. | — | 2018 | → |
| Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. | Celli BR et al. | — | 2018 | → |
| Gender differences in chronic obstructive pulmonary diseases: a narrative review. | Nicolini A et al. | — | 2018 | → |
| High Imminent Vertebral Fracture Risk in Subjects With COPD With a Prevalent or Incident Vertebral Fracture. | van Dort MJ et al. | — | 2018 | → |
| Interdependence of physical inactivity, loss of muscle mass and low dietary intake: Extrapulmonary manifestations in older chronic obstructive pulmonary disease patients. | Yoshimura K et al. | — | 2018 | → |
| Investigating Fractional Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease (COPD) and Asthma-COPD Overlap (ACO): A Scoping Review. | Mostafavi-Pour-Manshadi SM et al. | — | 2018 | → |
| Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD. | Aliagas E et al. | — | 2018 | → |
| Long-term outcomes following first short-term clinically important deterioration in COPD. | Naya IP et al. | — | 2018 | → |
| N-glycosylation patterns of plasma proteins and immunoglobulin G in chronic obstructive pulmonary disease. | Pavić T et al. | — | 2018 | → |
| Overfitting and Use of Mismatched Cohorts in Deep Learning Models: Preventable Design Limitations. | Mummadi SR et al. | — | 2018 | → |
| Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β<sub>2</sub>-Agonist Therapy: An Integrated Post Hoc Analysis. | Naya IP et al. | — | 2018 | → |
| Radiographic Emphysema, Circulating Bone Biomarkers, and Progressive Bone Mineral Density Loss in Smokers. | Bon J et al. | — | 2018 | → |
| Systemic Markers of Adaptive and Innate Immunity Are Associated with Chronic Obstructive Pulmonary Disease Severity and Spirometric Disease Progression. | Halper-Stromberg E et al. | — | 2018 | → |
| Total Airway Count on Computed Tomography and the Risk of Chronic Obstructive Pulmonary Disease Progression. Findings from a Population-based Study. | Kirby M et al. | — | 2018 | → |
| Altered regulation and expression of genes by BET family of proteins in COPD patients. | Malhotra R et al. | — | 2017 | → |
| A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. | Lal C et al. | — | 2017 | → |
| Ayurgenomics for stratified medicine: TRISUTRA consortium initiative across ethnically and geographically diverse Indian populations. | Prasher B et al. | — | 2017 | → |
| Biomarkers of collagen turnover are related to annual change in FEV<sub>1</sub> in patients with chronic obstructive pulmonary disease within the ECLIPSE study. | Leeming DJ et al. | — | 2017 | → |
| Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD. | Bihlet AR et al. | — | 2017 | → |
| Chest computed tomography-derived low fat-free mass index and mortality in COPD. | McDonald MN et al. | — | 2017 | → |
| Chronic Diseases and Lifestyle Biomarkers Identification by Metabolomics. | Mastrangelo A et al. | — | 2017 | → |
| Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. | Kim SH et al. | — | 2017 | → |
| Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies. | Rossi A et al. | — | 2017 | → |
| Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation. | Alcaide AB et al. | — | 2017 | → |
| Cohort Profile: The Birmingham Chronic Obstructive Pulmonary Disease (COPD) Cohort Study. | Adab P et al. | — | 2017 | → |
| COPD exacerbator phenotype: time for reassessment? | Nachef Z et al. | — | 2017 | → |
| CT imaging of chronic obstructive pulmonary disease: insights, disappointments, and promise. | Washko GR et al. | — | 2017 | → |
| Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. | Tabberer M et al. | — | 2017 | → |
| Do COPD subtypes really exist? COPD heterogeneity and clustering in 10 independent cohorts. | Castaldi PJ et al. | — | 2017 | → |
| Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy. | Martin M et al. | — | 2017 | → |
| Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. | Monaco TJ et al. | — | 2017 | → |
| Estimating drivers of cell state transitions using gene regulatory network models. | Schlauch D et al. | — | 2017 | → |
| Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. | Parulekar AD et al. | — | 2017 | → |
| Exhaled breath condensate as a potential biomarker tool for idiopathic pulmonary fibrosis-a pilot study. | Rindlisbacher B et al. | — | 2017 | → |
| Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. | Busch R et al. | — | 2017 | → |
| Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. | Wain LV et al. | — | 2017 | → |
| Incidence and relative risk for developing cancer among patients with COPD: a nationwide cohort study in Taiwan. | Ho CH et al. | — | 2017 | → |
| Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. | Silkoff PE et al. | — | 2017 | → |
| Integrative Genomics of Emphysema-Associated Genes Reveals Potential Disease Biomarkers. | Obeidat M et al. | — | 2017 | → |
| Management of COPD: Is there a role for quantitative imaging? | Kirby M et al. | — | 2017 | → |
| Meta-analysis of peripheral blood gene expression modules for COPD phenotypes. | Reinhold D et al. | — | 2017 | → |
| Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast. | Facius A et al. | — | 2017 | → |
| Multiple biomarkers predict disease severity, progression and mortality in COPD. | Zemans RL et al. | — | 2017 | → |
| Network-based analysis reveals novel gene signatures in peripheral blood of patients with chronic obstructive pulmonary disease. | Obeidat M et al. | — | 2017 | → |
| Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma. | Farahi N et al. | — | 2017 | → |
| Percent Emphysema and Daily Motor Activity Levels in the General Population: Multi-Ethnic Study of Atherosclerosis. | Lo Cascio CM et al. | — | 2017 | → |
| Post Hoc: Two (or More) for the Price of One. | Stockley RA | — | 2017 | → |
| Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. | Hoogendoorn M et al. | — | 2017 | → |
| Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. | Ficker JH et al. | — | 2017 | → |
| Screening for interaction effects in gene expression data. | Castaldi PJ et al. | — | 2017 | → |
| Sex-Based Genetic Association Study Identifies CELSR1 as a Possible Chronic Obstructive Pulmonary Disease Risk Locus among Women. | Hardin M et al. | — | 2017 | → |
| Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study. | Reilev M et al. | — | 2017 | → |
| Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. | Exuzides A et al. | — | 2017 | → |
| The association of tidal EFL with exercise performance, exacerbations, and death in COPD. | Aarli BB et al. | — | 2017 | → |
| The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset. | Tabberer M et al. | — | 2017 | → |
| The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. | Martinez FJ et al. | — | 2017 | → |
| The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions. | Bognar K et al. | — | 2017 | → |
| Accuracy of forced oscillation technique to assess lung function in geriatric COPD population. | Tse HN et al. | — | 2016 | → |
| A comparison of COPD patients with and without ACOS in the ECLIPSE study. | Wurst KE et al. | — | 2016 | → |
| A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease. | Hardin M et al. | — | 2016 | → |
| Alterations in Serum Polyunsaturated Fatty Acids and Eicosanoids in Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD). | Titz B et al. | — | 2016 | → |
| An ECLIPSE View of Alpha-1 Antitrypsin Deficiency. | Lomas DA | — | 2016 | → |
| A new perspective on COPD exacerbations: monitoring impact by measuring physical, psychological and social resilience. | Spruit MA et al. | — | 2016 | → |
| Association Between Interstitial Lung Abnormalities and All-Cause Mortality. | Putman RK et al. | — | 2016 | → |
| Biobehavioral Prognostic Factors in Chronic Obstructive Pulmonary Disease: Results From the INSPIRE-II Trial. | Blumenthal JA et al. | — | 2016 | → |
| Body mass index, airflow obstruction and dyspnea and body mass index, airflow obstruction, dyspnea scores, age and pack years-predictive properties of new multidimensional prognostic indices of chronic obstructive pulmonary disease in primary care. | Ansari K et al. | — | 2016 | → |
| Characteristics of elderly patients with COPD and newly diagnosed lung cancer, and factors associated with treatment decision. | Qin J et al. | — | 2016 | → |
| Choose your outcomes: From the mean to the personalized assessment of outcomes in COPD. An exploratory pragmatic survey. | Braido F et al. | — | 2016 | → |
| Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. | Rabinovich RA et al. | — | 2016 | → |
| COPD subtypes identified by network-based clustering of blood gene expression. | Chang Y et al. | — | 2016 | → |
| Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. | Miravitlles M et al. | — | 2016 | → |
| Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. | Andrianopoulos V et al. | — | 2016 | → |
| Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. | Selya-Hammer C et al. | — | 2016 | → |
| Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency. | Chorostowska-Wynimko J | — | 2016 | → |
| Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. | Kreindler JL et al. | — | 2016 | → |
| Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. | Tan WC et al. | — | 2016 | → |
| Free Urinary Desmosine and Isodesmosine as COPD Biomarkers: The Relevance of Confounding Factors. | Ongay S et al. | — | 2016 | → |
| Hemizygous Deletion on Chromosome 3p26.1 Is Associated with Heavy Smoking among African American Subjects in the COPDGene Study. | Begum F et al. | — | 2016 | → |
| High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD - results from the ECLIPSE study. | Sand JM et al. | — | 2016 | → |
| Identification of five clusters of comorbidities in a longitudinal Japanese chronic obstructive pulmonary disease cohort. | Chubachi S et al. | — | 2016 | → |
| Identifying a Deletion Affecting Total Lung Capacity Among Subjects in the COPDGene Study Cohort. | Begum F et al. | — | 2016 | → |
| Importance of fractional exhaled nitric oxide in the differentiation of asthma-COPD overlap syndrome, asthma, and COPD. | Chen FJ et al. | — | 2016 | → |
| Measuring Airway Remodeling in Patients With Different COPD Staging Using Endobronchial Optical Coherence Tomography. | Ding M et al. | — | 2016 | → |
| Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. | Han MK et al. | — | 2016 | → |
| Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. | Cloonan SM et al. | — | 2016 | → |
| Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. | Miller BE et al. | — | 2016 | → |
| Pulmonary Artery Abnormalities in Ex-smokers with and without Airflow Obstruction. | Lindenmaier TJ et al. | — | 2016 | → |
| Quantitative Assessment of Erector Spinae Muscles in Patients with Chronic Obstructive Pulmonary Disease. Novel Chest Computed Tomography-derived Index for Prognosis. | Tanimura K et al. | — | 2016 | → |
| Quantitative computed tomography imaging in chronic obstructive pulmonary disease. | Fernandes L et al. | — | 2016 | → |
| SABRE: a method for assessing the stability of gene modules in complex tissues and subject populations. | Shannon CP et al. | — | 2016 | → |
| Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease. | Joppa P et al. | — | 2016 | → |
| Sex Difference in Chronic Obstructive Lung Disease. Does it Matter? A Concise Review. | Kokturk N et al. | — | 2016 | → |
| Surfactant protein D, a clinical biomarker for chronic obstructive pulmonary disease with excellent discriminant values. | Akiki Z et al. | — | 2016 | → |
| The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease. | Obeidat M et al. | — | 2016 | → |
| This is what COPD looks like. | Sheikh K et al. | — | 2016 | → |
| Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study. | Labonté LE et al. | — | 2016 | → |
| Ventilation Heterogeneity in Never-smokers and COPD:: Comparison of Pulmonary Functional Magnetic Resonance Imaging with the Poorly Communicating Fraction Derived From Plethysmography. | Davis C et al. | — | 2016 | → |
| A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry. | Lutz SM et al. | — | 2015 | → |
| A Genome-Wide Association Study of Emphysema and Airway Quantitative Imaging Phenotypes. | Cho MH et al. | — | 2015 | → |
| Alterations in the sputum proteome and transcriptome in smokers and early-stage COPD subjects. | Titz B et al. | — | 2015 | → |
| Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease. | Asai K et al. | — | 2015 | → |
| Application of nitric oxide measurements in clinical conditions beyond asthma. | Malinovschi A et al. | — | 2015 | → |
| Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. | Benson VS et al. | — | 2015 | → |
| Biomarkers for precision medicine in airways disease. | Rooney C et al. | — | 2015 | → |
| Bioregulatory systems medicine: an innovative approach to integrating the science of molecular networks, inflammation, and systems biology with the patient's autoregulatory capacity? | Goldman AW et al. | — | 2015 | → |
| Chronic Obstructive Pulmonary Disease: Pulmonary Function and CT Lung Attenuation Do Not Show Linear Correlation. | Paoletti M et al. | — | 2015 | → |
| Clinical and prognostic heterogeneity of C and D GOLD groups. | Agustí A et al. | — | 2015 | → |
| Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD. | Bihlet AR et al. | — | 2015 | → |
| Continuous fat-free mass decline in COPD: fact or fiction? | Rutten EP et al. | — | 2015 | → |
| COPD: Do Imaging Measurements of Emphysema and Airway Disease Explain Symptoms and Exercise Capacity? | Kirby M et al. | — | 2015 | → |
| Correlation Between Emphysema and Lung Function in Healthy Smokers and Smokers With COPD. | Thomsen LH et al. | — | 2015 | → |
| CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society. | Lynch DA et al. | — | 2015 | → |
| CT Scanning in COPD - Is it Time to Move On? | Come CE et al. | — | 2015 | → |
| Dissecting the genetics of chronic mucus hypersecretion in smokers with and without COPD. | Dijkstra AE et al. | — | 2015 | → |
| Does Improving Exercise Capacity and Daily Activity Represent the Holistic Perspective of a New COPD Approach? | Di Marco F et al. | — | 2015 | → |
| Do females behave differently in COPD exacerbation? | Kilic H et al. | — | 2015 | → |
| Evaluation of the COPD Assessment Test and GOLD patient types: a cross-sectional analysis. | Lopez-Campos JL et al. | — | 2015 | → |
| Free-breathing pulmonary 1H and Hyperpolarized 3He MRI: comparison in COPD and bronchiectasis. | Capaldi DP et al. | — | 2015 | → |
| Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. | Müllerova H et al. | — | 2015 | → |
| Hyperpolarized 83Kr magnetic resonance imaging of alveolar degradation in a rat model of emphysema. | Lilburn DM et al. | — | 2015 | → |
| Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. | Rennard SI et al. | — | 2015 | → |
| Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. | Lim S et al. | — | 2015 | → |
| IREB2 and GALC are associated with pulmonary artery enlargement in chronic obstructive pulmonary disease. | Lee JH et al. | — | 2015 | → |
| Large trials, new knowledge: the changing face of COPD management. | De Soyza A et al. | — | 2015 | → |
| Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. | de-Torres JP et al. | — | 2015 | → |
| Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium. | Lopez-Campos JL et al. | — | 2015 | → |
| Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations. | Katajisto M et al. | — | 2015 | → |
| Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. | Mannino DM et al. | — | 2015 | → |
| Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. | Andrianopoulos V et al. | — | 2015 | → |
| Protocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: monitoring the nasal and systemic immune response using a network biology approach. | Ross CL et al. | — | 2015 | → |
| Pulmonary abnormalities and carotid atherosclerosis in ex-smokers without airflow limitation. | Pike D et al. | — | 2015 | → |
| Secondhand Tobacco Smoke and COPD Risk in Smokers: A COPDGene Study Cohort Subgroup Analysis. | van Koeverden I et al. | — | 2015 | → |
| Study on risk factors and phenotypes of acute exacerbations of chronic obstructive pulmonary disease in Guangzhou, China-design and baseline characteristics. | Zhou Y et al. | — | 2015 | → |
| Survey to determine the efficacy and safety of guideline-based pharmacological therapy for chronic obstructive pulmonary disease patients not previously receiving maintenance treatment. | Setoguchi Y et al. | — | 2015 | → |
| The Effect of Statins on Blood Gene Expression in COPD. | Obeidat M et al. | — | 2015 | → |
| The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. | Nobakht M Gh BF et al. | — | 2015 | → |
| The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methods. | Kardos P et al. | — | 2015 | → |
| Ultra-short echo-time pulmonary MRI: evaluation and reproducibility in COPD subjects with and without bronchiectasis. | Ma W et al. | — | 2015 | → |
| Variability of within-breath reactance in COPD patients and its association with dyspnoea. | Aarli BB et al. | — | 2015 | → |
| Acute Exacerbation and Respiratory InfectionS in COPD (AERIS): protocol for a prospective, observational cohort study. | Bourne S et al. | — | 2014 | → |
| A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease. | Menche J et al. | — | 2014 | → |
| Airway wall area derived from 3-dimensional computed tomography analysis differs among lung lobes in male smokers. | Tho NV et al. | — | 2014 | → |
| Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort. | Singh D et al. | — | 2014 | → |
| An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. | Wells JM et al. | — | 2014 | → |
| Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling. | Merali S et al. | — | 2014 | → |
| Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD. | Chu JH et al. | — | 2014 | → |
| Association between vitamin D status and COPD phenotypes. | Moberg M et al. | — | 2014 | → |
| Beyond GWAS in COPD: probing the landscape between gene-set associations, genome-wide associations and protein-protein interaction networks. | McDonald ML et al. | — | 2014 | → |
| Chest CT measures of muscle and adipose tissue in COPD: gender-based differences in content and in relationships with blood biomarkers. | Diaz AA et al. | — | 2014 | → |
| Chronic Obstructive Pulmonary Disease heterogeneity: challenges for health risk assessment, stratification and management. | Roca J et al. | — | 2014 | → |
| Clinical issues of mucus accumulation in COPD. | Ramos FL et al. | — | 2014 | → |
| Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. | McDonald ML et al. | — | 2014 | → |
| Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. | Koskela J et al. | — | 2014 | → |
| Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. | Williams MC et al. | — | 2014 | → |
| Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). | Couper D et al. | — | 2014 | → |
| DNAH5 is associated with total lung capacity in chronic obstructive pulmonary disease. | Lee JH et al. | — | 2014 | → |
| Eosinophilic inflammation in COPD: prevalence and clinical characteristics. | Singh D et al. | — | 2014 | → |
| Evaluating the role of inflammation in chronic airways disease: the ERICA study. | Mohan D et al. | — | 2014 | → |
| Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease. | Lee JH et al. | — | 2014 | → |
| Hyperpolarized 3He and 129Xe magnetic resonance imaging apparent diffusion coefficients: physiological relevance in older never- and ex-smokers. | Kirby M et al. | — | 2014 | → |
| Hyperpolarized (3)He ventilation defects used to predict pulmonary exacerbations in mild to moderate chronic obstructive pulmonary disease. | Kirby M et al. | — | 2014 | → |
| Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis. | Raju SV et al. | — | 2014 | → |
| Integrative genomics of chronic obstructive pulmonary disease. | Hobbs BD et al. | — | 2014 | → |
| Lessons from ECLIPSE: a review of COPD biomarkers. | Faner R et al. | — | 2014 | → |
| Longitudinal Computed Tomography and Magnetic Resonance Imaging of COPD: Thoracic Imaging Network of Canada (TINCan) Study Objectives. | Kirby M et al. | — | 2014 | → |
| Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. | Johansson SL et al. | — | 2014 | → |
| Moving towards patient-centered medicine for COPD management: multidimensional approaches versus phenotype-based medicine--a critical view. | Lopez-Campos JL et al. | — | 2014 | → |
| Network medicine, multimorbidity and the lung in the elderly. | Faner R et al. | — | 2014 | → |
| Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. | Hersh CP et al. | — | 2014 | → |
| Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. | Janssen DJ et al. | — | 2014 | → |
| Physical activity and longitudinal change in 6-min walk distance in COPD patients. | Frisk B et al. | — | 2014 | → |
| Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. | Kruis AL et al. | — | 2014 | → |
| Progress in Imaging COPD, 2004 - 2014. | Lynch DA | — | 2014 | → |
| Quantitative (1)H and hyperpolarized (3)He magnetic resonance imaging: comparison in chronic obstructive pulmonary disease and healthy never-smokers. | Owrangi AM et al. | — | 2014 | → |
| Quantitative computed tomography measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease. A cross-sectional study. | McDonald ML et al. | — | 2014 | → |
| Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. | Tashkin DP | — | 2014 | → |
| Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. | Vestbo J et al. | — | 2014 | → |
| Survival in COPD: impact of lung dysfunction and comorbidities. | Miniati M et al. | — | 2014 | → |
| Susceptibility to chronic mucus hypersecretion, a genome wide association study. | Dijkstra AE et al. | — | 2014 | → |
| The application of impulse oscillation system for the evaluation of treatment effects in patients with COPD. | Mineshita M et al. | — | 2014 | → |
| Acute and chronic inflammatory responses induced by smoking in individuals susceptible and non-susceptible to development of COPD: from specific disease phenotyping towards novel therapy. Protocol of a cross-sectional study. | Lo Tam Loi AT et al. | — | 2013 | → |
| Analysis of chloroformate-derivatised amino acids, dipeptides and polyamines by LC-MS/MS. | Ubhi BK et al. | — | 2013 | → |
| Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling. | Bloomer JC et al. | — | 2013 | → |
| Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. | Brightling CE | — | 2013 | → |
| Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. | Agusti A et al. | — | 2013 | → |
| Chronic obstructive pulmonary disease: more imaging, more phenotyping...better care? | Pike D et al. | — | 2013 | → |
| Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. | Miller J et al. | — | 2013 | → |
| Computed tomography as a biomarker in clinical trials imaging. | Goldin JG | — | 2013 | → |
| COPD and disease-specific health status in a working population. | Nishimura K et al. | — | 2013 | → |
| CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. | Romme EA et al. | — | 2013 | → |
| Diagnosis of chronic obstructive pulmonary disease, simpler is better. Complexity and simplicity. | Clini EM et al. | — | 2013 | → |
| Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. | Siedlinski M et al. | — | 2013 | → |
| Elastin degradation products as biomarkers in alpha-1 antitrypsin deficiency: lastin' impact? | Stoller JK | — | 2013 | → |
| Factors associated with change in exacerbation frequency in COPD. | Donaldson GC et al. | — | 2013 | → |
| FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. | Agusti A et al. | — | 2013 | → |
| Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. | Minas M et al. | — | 2013 | → |
| High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study. | Zheng JP et al. | — | 2013 | → |
| Impact of emphysema and airway wall thickness on quality of life in smoking-related COPD. | Gietema HA et al. | — | 2013 | → |
| Lung function indices for predicting mortality in COPD. | Boutou AK et al. | — | 2013 | → |
| Nitric oxide synthase polymorphisms, gene expression and lung function in chronic obstructive pulmonary disease. | Aminuddin F et al. | — | 2013 | → |
| Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations. | Bloomer J et al. | — | 2013 | → |
| Paired inspiratory-expiratory chest CT scans to assess for small airways disease in COPD. | Hersh CP et al. | — | 2013 | → |
| Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD. | Wells JM et al. | — | 2013 | → |
| Phenotyping the heterogeneity of chronic obstructive pulmonary disease. | Barker BL et al. | — | 2013 | → |
| Predictors of the need to initiate noninvasive ventilation in stable outpatients with acute exacerbation of chronic obstructive pulmonary disease. | Taga S et al. | — | 2013 | → |
| Pulmonary emphysema in cystic fibrosis detected by densitometry on chest multidetector computed tomography. | Wielpütz MO et al. | — | 2013 | → |
| Recent advances in α-1-antitrypsin deficiency-related lung disease. | Brebner JA et al. | — | 2013 | → |
| Reply: minimal or maximal clinically important difference: using death to define MCID. | Polkey MI et al. | — | 2013 | → |
| Semi-automated scoring of pulmonary emphysema from X-ray CT: trainee reproducibility and accuracy. | Owrangi AM et al. | — | 2013 | → |
| Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. | Polkey MI et al. | — | 2013 | → |
| Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. | MacNee W | — | 2013 | → |
| Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. | Cheng DT et al. | — | 2013 | → |
| The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. | Coxson HO et al. | — | 2013 | → |
| The role of desmosines as biomarkers for chronic obstructive pulmonary disease. | Iadarola P et al. | — | 2013 | → |
| About the role of indacaterol in obstructive airways disorder: CON. | Reis Ferreira JM | — | 2012 | → |
| A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. | COPDGene CT Workshop Group et al. | — | 2012 | → |
| A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. | Cho MH et al. | — | 2012 | → |
| Chronic obstructive pulmonary disease: CT quantification of airways disease. | Hackx M et al. | — | 2012 | → |
| Chronic obstructive pulmonary disease history assessment in Spain: a multidimensional chronic obstructive pulmonary disease evaluation. Study methods and organization. | López-Campos JL et al. | — | 2012 | → |
| Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe. | Rubio JP et al. | — | 2012 | → |
| Development of the Shortness of Breath with Daily Activities questionnaire (SOBDA). | Howard K et al. | — | 2012 | → |
| Dysregulated adipokine metabolism in chronic obstructive pulmonary disease. | Breyer MK et al. | — | 2012 | → |
| Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. | Al-shair K et al. | — | 2012 | → |
| Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. | Basanta M et al. | — | 2012 | → |
| Genes and chronic obstructive pulmonary disease. | Foreman MG et al. | — | 2012 | → |
| Genetic association between human chitinases and lung function in COPD. | Aminuddin F et al. | — | 2012 | → |
| Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. | Kim DK et al. | — | 2012 | → |
| High-resolution computed tomography quantitation of emphysema is correlated with selected lung function values in stable COPD. | D'Anna SE et al. | — | 2012 | → |
| Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. | Celli BR et al. | — | 2012 | → |
| Metabolic profiling detects biomarkers of protein degradation in COPD patients. | Ubhi BK et al. | — | 2012 | → |
| New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses. | Mapel DW et al. | — | 2012 | → |
| Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. | Agustí A et al. | — | 2012 | → |
| Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. | Waschki B et al. | — | 2012 | → |
| Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. | Spruit MA et al. | — | 2012 | → |
| Pulmonary arterial enlargement and acute exacerbations of COPD. | Wells JM et al. | — | 2012 | → |
| Recent findings in chronic obstructive pulmonary disease by using quantitative computed tomography. | Van Tho N et al. | — | 2012 | → |
| Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. | Röpcke S et al. | — | 2012 | → |
| Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. | Agustí A et al. | — | 2012 | → |
| Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. | Ubhi BK et al. | — | 2012 | → |
| The EvA study: aims and strategy. | Ziegler-Heitbrock L et al. | — | 2012 | → |
| Using computed tomography to measure the site of airflow obstruction. | Coxson HO | — | 2012 | → |
| Variability in COPD: the PLATINO study viewpoint. | López Varela MV et al. | — | 2012 | → |
| Variation in quantitative CT air trapping in heavy smokers on repeat CT examinations. | Mets OM et al. | — | 2012 | → |
| Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. | Agusti A et al. | — | 2011 | → |
| Assessment of small-airways disease using alveolar nitric oxide and impulse oscillometry in asthma and COPD. | Williamson PA et al. | — | 2011 | → |
| Changes in forced expiratory volume in 1 second over time in COPD. | Vestbo J et al. | — | 2011 | → |
| Controversies in treatment of chronic obstructive pulmonary disease. | Rabe KF et al. | — | 2011 | → |
| COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. | Dickens JA et al. | — | 2011 | → |
| Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. | Hanania NA et al. | — | 2011 | → |
| Elevated airway purines in COPD. | Esther CR et al. | — | 2011 | → |
| Evaluation of exhaled breath condensate pH as a biomarker for COPD. | MacNee W et al. | — | 2011 | → |
| Evaluation of full-length, cleaved and nitrosylated serum surfactant protein D as biomarkers for COPD. | Duvoix A et al. | — | 2011 | → |
| Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD. | Bazeghi N et al. | — | 2011 | → |
| Genetics of sputum gene expression in chronic obstructive pulmonary disease. | Qiu W et al. | — | 2011 | → |
| Genome-wide association analysis of body mass in chronic obstructive pulmonary disease. | Wan ES et al. | — | 2011 | → |
| Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. | Kong X et al. | — | 2011 | → |
| Genome-wide association study of smoking behaviours in patients with COPD. | Siedlinski M et al. | — | 2011 | → |
| Identification of FGF7 as a novel susceptibility locus for chronic obstructive pulmonary disease. | Brehm JM et al. | — | 2011 | → |
| Insights into COPD comorbidities from the OLIN study and other large databases. | Mapel D | — | 2011 | → |
| Investigation of four-dimensional computed tomography-based pulmonary ventilation imaging in patients with emphysematous lung regions. | Yamamoto T et al. | — | 2011 | → |
| Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. | de Torres JP et al. | — | 2011 | → |
| Multidimensional prognostic indices for use in COPD patient care. A systematic review. | Dijk WD et al. | — | 2011 | → |
| Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials. | Woodruff PG | — | 2011 | → |
| On the follow-up of genome-wide association studies: an overall test for the most promising SNPs. | Lipman PJ et al. | — | 2011 | → |
| Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. | Silverman EK et al. | — | 2011 | → |
| Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. | Foreman MG et al. | — | 2011 | → |
| Predictors of depression in chronic obstructive pulmonary disease patients. | Antoniu SA | — | 2011 | → |
| Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. | Gietema HA et al. | — | 2011 | → |
| Quantifying the extent of emphysema "open the pod door, Hal". | Brown RH | — | 2011 | → |
| Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. | Rennard SI et al. | — | 2011 | → |
| Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. | Crim C et al. | — | 2011 | → |
| Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations. | Field SK | — | 2011 | → |
| Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. | Sin DD et al. | — | 2011 | → |
| Small airway disease in asthma: a need for awareness in patients and doctors. | van den Berge M et al. | — | 2011 | → |
| Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. | Miniati M et al. | — | 2011 | → |
| The association of genome-wide significant spirometric loci with chronic obstructive pulmonary disease susceptibility. | Castaldi PJ et al. | — | 2011 | → |
| The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. | Cave AC et al. | — | 2011 | → |
| Variable loss of lung function in COPD. | Burney P | — | 2011 | → |
| Case-control studies on risk factors for chronic obstructive pulmonary disease: how does the sampling of the cases and controls affect the results? | Sørheim IC et al. | — | 2010 | → |
| Characterisation of COPD heterogeneity in the ECLIPSE cohort. | Agusti A et al. | — | 2010 | → |
| Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. | Vestbo J et al. | — | 2010 | → |
| Chronic obstructive pulmonary disease: longitudinal hyperpolarized (3)He MR imaging. | Kirby M et al. | — | 2010 | → |
| [Clinical phenotypes of COPD]. | Sobradillo P et al. | — | 2010 | → |
| Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. | Spruit MA et al. | — | 2010 | → |
| Frequent exacerbations of chronic obstructive pulmonary disease--a distinct phenotype? | Tashkin DP | — | 2010 | → |
| Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. | Price DB et al. | — | 2010 | → |
| Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. | Pillai SG et al. | — | 2010 | → |
| Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. | Saccone NL et al. | — | 2010 | → |
| Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). | Hanania NA et al. | — | 2010 | → |
| Self-rated health predicts acute exacerbations and hospitalizations in patients with COPD. | Farkas J et al. | — | 2010 | → |
| Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. | Singh D et al. | — | 2010 | → |
| Susceptibility to exacerbation in chronic obstructive pulmonary disease. | Hurst JR et al. | — | 2010 | → |
| Treatment of COPD: from pharmacological to instrumental therapies. | Alifano M et al. | — | 2010 | → |
| Variants in FAM13A are associated with chronic obstructive pulmonary disease. | Cho MH et al. | — | 2010 | → |
| Biomarkers of lung damage associated with tobacco smoke in induced sputum. | Comandini A et al. | — | 2009 | → |
| [Causes of mortality in COPD]. | Soriano Ortiz JB et al. | — | 2009 | → |
| Chronic obstructive pulmonary disease: towards pharmacogenetics. | Wood AM et al. | — | 2009 | → |
| [COPD and systemic inflammation. A link for comorbidity]. | Agustí A | — | 2009 | → |
| [COPD: what is there beyond BODE index?]. | Casanova Macario C et al. | — | 2009 | → |
| Current world literature. | — | — | 2009 | → |
| Emerging drugs in chronic obstructive pulmonary disease. | Seifart C et al. | — | 2009 | → |
| Global assessment of the COPD patient: time to look beyond FEV1? | Papaioannou AI et al. | — | 2009 | → |
| Markers of early disease and prognosis in COPD. | Dahl M et al. | — | 2009 | → |
| New and current clinical imaging techniques to study chronic obstructive pulmonary disease. | Coxson HO et al. | — | 2009 | → |
| Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. | Stockley RA | — | 2009 | → |
| Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. | Bourdin A et al. | — | 2009 | → |
| Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. | Lomas DA et al. | — | 2009 | → |
| The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. | Bon JM et al. | — | 2009 | → |
| Update in chronic obstructive pulmonary disease 2008. | Maclay JD et al. | — | 2009 | → |
| Biomarkers in exhaled breath condensate: a review of collection, processing and analysis. | Grob NM et al. | — | 2008 | → |
| Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. | Luisetti M et al. | — | 2008 | → |
| The many "small COPDs": COPD should be an orphan disease. | Rennard SI et al. | — | 2008 | → |